IA-Assistance Publique - Hôpitaux de Paris

IA-Assistance Publique - Hôpitaux de Paris refers to a specific therapeutic intervention protocol developed by Assistance Publique - Hôpitaux de Paris (AP-HP) for the treatment of severe pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. This intervention is a combination therapy consisting of immunoadsorption (IA) and the monoclonal antibody rituximab. Immunoadsorption is an extracorporeal blood purification procedure that utilizes specialized adsorber columns (such as Therasorb) to selectively remove pathogenic anti-NMDAR autoantibodies from the patient's circulation. Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B-lymphocytes, is administered concomitantly to deplete the B-cell population responsible for producing these autoantibodies. This dual-action approach is intended as a second-line therapy for pediatric patients who have failed first-line immunotherapy, such as corticosteroids or intravenous immunoglobulins (IVIg).

Other names

Immunoadsorption + RituximabIA-Rituximab combination therapyTherasorb